Bacterial Pneumonia and Cryptogenic Pleuritis after Probable Monkeypox Virus Infection: A Case Report

A large number of monkeypox (MPOX) cases have been reported in Europe and North America in 2022, and a new outbreak of this disease was declared. We describe a case of a patient with probable monkeypox during the height of this epidemic in Poland. The patient's symptoms resolved within two weeks, but over the next two months, he developed community-acquired pneumonia requiring hospitalization and, subsequently, non-specific pleuritis. The simultaneous occurrence of such severe infections in a previously healthy young man is not typical and suggests a potential underlying cause. We believe the potential association of these diseases with probable monkeypox virus infection is very likely. Cases of monkeypox pneumonia, both viral and secondary bacterial, have already been reported in the literature. Cases of viral pleuritis in the course of MPOX in animals have also been described; however, to our knowledge, no similar cases have been described in humans to date. Our case indicates that it is important to monitor patients after MPOX in order to respond promptly to potentially life-threatening but, as of yet, not fully understood complications.

Nocturnal Hypoventilation in the Patients Submitted to Thoracic Surgery

Introduction

Nocturnal hypoventilation may occur due to obesity, concomitant chronic obstructive pulmonary disease (COPD), obstructive sleep apnea, and/or the use of narcotic analgesics. The aim of the study was to evaluate the risk and severity of nocturnal hypoventilation as assessed by transcutaneous continuous capnography in the patients submitted to thoracic surgery.

Materials and Methods

The material of the study consisted of 45 obese (BMI 34.8 ± 3.7 kg/m2) and 23 nonobese (25.5 ± 3.6 kg/m2) patients, who underwent thoracic surgery because of malignant (57 patients) and nonmalignant tumors. All the patients received routine analgesic treatment after surgery including intravenous morphine sulfate. Overnight transcutaneous measurements of CO2 partial pressure (tcpCO2) were performed before and after surgery in search of nocturnal hypoventilation, i.e., the periods lasting at least 10 minutes with tcpCO2 above 55 mmHg.

Results

Nocturnal hypoventilation during the first night after thoracic surgery was detected in 10 patients (15%), all obese, three of them with COPD, four with high suspicion of moderate-to-severe OSA syndrome, and one with chronic daytime hypercapnia. In the patients with nocturnal hypoventilation, the mean tcpCO2 was 53.4 ± 6.1 mmHg, maximal tcpCO2 was 59.9 ± 8.4 mmHg, and minimal tcpCO2 was 46.4 ± 6.7 mmHg during the first night after surgery. In these patients, there were higher values of minimal, mean, and maximal tcpCO2 in the preoperative period. Nocturnal hypoventilation in the postoperative period did not influence the duration of hospitalization. Among 12 patients with primary lung cancer who died during the first two years of observation, there were 11 patients without nocturnal hypoventilation in the early postoperative period.

Conclusion

Nocturnal hypoventilation may occur in the patients after thoracic surgery, especially in obese patients with bronchial obstruction, obstructive sleep apnea, or chronic daytime hypercapnia, and does not influence the duration of hospitalization.

Cryptosporidium baileyi Pulmonary Infection in Immunocompetent Woman with Benign Neoplasm

Cryptosporidium baileyi, a bird-specific parasite, infects gastrointestinal, pulmonary, and urinary tracts of its host. We report on a C. baileyi infection associated with pulmonary hamartoma in an immunocompetent patient in Poland. Further work is needed to investigate the association between Cryptosporidium infections and tumors.

Pulmonary rehabilitation in interstitial lung diseases: A review of the literature

There are more than 200 different diseases classed as interstitial lung diseases (ILDs). For epidemiological and practical purposes, ILDs are classified into diseases of known and unknown etiology. The aim of this review is to evaluate our current knowledge about the efficacy and safety of pulmonary rehabilitation (PR) in patients with ILDs. Other issues, such as ILD pathogenesis, prevalence and comorbidity, are also elaborated in the review. Pulmonary rehabilitation is an important part of comprehensive care for patients with ILDs. In comparison to PR for patients with chronic pulmonary obstructive disease (COPD), the number of clinical studies concerning PR for patients with ILDs is small. The majority of trials have been performed in relatively small groups of patients. The principles of PR in this group of patients are the same as for patients with COPD. Exercise-induced desaturation is frequently observed during PR, which is the main source of complications in patients with ILDs. Major differences between ILD and COPD patients include poorer exercise tolerance and faster development of respiratory failure in patients with ILDs.

Prevalence and genotyping of Pneumocystis jirovecii in renal transplant recipients-preliminary report

Pneumocystis jirovecii is an opportunistic fungus occurring in human lungs. The group at highest risk consists of HIV-infected and non-HIV-infected immunosuppressed individuals. In these patients, P. jirovecii infection may lead to Pneumocystis pneumonia; it may, however, persist also in an asymptomatic form. This study aimed to determine the prevalence of P. jirovecii and potential risk factors for infection in a group of renal transplant recipients and to characterize the genetic diversity of this fungus in the studied population. Sputum specimens from 72 patients were tested for presence of P. jirovecii using immunofluorescence microscopy, as well as nested PCR targeting the mtLSU rRNA gene. Genotyping involving analysis of four loci—mtLSU rRNA, CYB, DHPS, and SOD—was used to characterize the diversity of the detected organisms. Pneumocystis DNA was detected in eight (11.11%) patients. It has been shown that low eosinophil count and dual immunosuppressive treatment combining prednisone and calcineurin inhibitors are potential risk factors for colonization. Analysis of genotype distribution showed an association of the wild-type genotype of mtLSU rRNA with lower average age of patients and shorter time after kidney transplantation. Furthermore, CYB 2 genotype was detected only in patients with the ongoing prophylaxis regimen. In conclusion, renal transplant recipients are at risk of Pneumocystis colonization even a long time after transplantation. The present preliminary study identifies specific polymorphisms that appear to be correlated with certain patient characteristics and highlights the need for deeper investigation of these associations in renal transplant recipients.

Symptomatic respiratory Encephalitozoon cuniculi infection in renal transplant recipients

OBJECTIVES

Encephalitozoon spp. and Enterocytozoon bieneusi are intracellular parasitic fungi from the phylum Microsporidia, which initially localize to the intestine. As opportunistic pathogens, Encephalitozoon spp. in particular can disseminate to the respiratory tract, among other locations. Patients on life-long immunosuppression are at higher risk of such infections, mostly symptomatic.

METHODS

Sputum samples and bronchial washings from 72 renal transplant recipients and 105 patients with various respiratory diseases were screened for Encephalitozoon spp. and E. bieneusi by microscopic examination and genus-specific nested PCR followed by genotyping.

RESULTS

A total of 8.3% (6/72) of immunosuppressed renal transplant recipients and 1.9% (2/105) of patients with various respiratory diseases, both immunocompetent and immunosuppressed, were positive for respiratory microsporidial infection. All six transplant recipients were Encephalitozoon cuniculi-positive by PCR/sequencing and five of them suffered from respiratory symptoms. The presence of microsporidial spores was also confirmed microscopically in three of the transplant recipients. Of the two immunocompetent patients with various respiratory diseases, one had an E. cuniculi infection, while the second had an E. bieneusi infection.

CONCLUSIONS

Life-long immunosuppression in renal transplant recipients increases the risk of respiratory infection by E. cuniculi. Microsporidia should be screened in respiratory samples of these patients, particularly when they have respiratory symptoms.

Correlations between osteoprotegerin serum levels and body composition parameters in patients with sleep apnea syndrome and the possible influence on cardiovascular risk

INTRODUCTION

Osteoprotegerin (OPG) is a member of the tumor necrosis factor family and a key regulator in bone turnover; it plays a role in the development of many cardiovascular diseases and may be treated as a marker of vascular damage. Bioelectrical impedance analysis (BIA) is a reliable, non-invasive and effective technique for measuring body composition. The aim of the study was to evaluate correlations between osteoprotegerin serum levels and body composition parameters in sleep apnea patients and their influence on cardiovascular risk.

MATERIAL AND METHODS

A total of 125 patients with newly diagnosed OSA were enrolled in the study (including 34 females). The mean age was 54.48±8.81 years, mean AHI 33.16±20.44/h and mean BMI 33.76±7.18. A control group comprised 59 healthy subjects with mean age of 51.27±12.97 years and mean BMI 29.47±5.42. All subjects underwent a nocturnal respiratory polygraphy and body composition measurements were taken with bioelectrical impedance analysis. OPG serum levels were measured using the enzyme-linked immunosorbent assay (ELISA) method.

RESULTS

In OSA patients OPG correlated negatively with muscle mass percentage (MM%), phase angle, fat free mass percentage (FFM%) and body cell mass percentage (BCM%), while there was a positive correlation between osteoprotegerin and fat mass percentage (FM%). We demonstrated higher OPG serum levels in OSA patients with cardiovascular diseases than in those without comorbidities (4.01 vs 3.46pmol/l, p<0.05).

CONCLUSION

Our findings, combined with previous observations in other diseases, suggest that elevated OPG serum levels together with selected body composition parameters may be helpful in identifying OSA patients with increased cardiovascular risk.

Nocturnal parasympathetic modulation of heart rate in obesity-hypoventilation patients

Heart rate variation (HRV) reflects the activity of the autonomic nervous system. The aim of the study was to analyze HRV in obstructive sleep apnea (OSA) and obesity hypoventilation (OH) patients to answer the question of whether chronic alveolar hypoventilation influences autonomic heart rate regulation. In 41 patients, diagnosed with either 'pure' OSA (n=23, apnea/hypopnea index--AHI: 43.8±18.0 PaCO2≤45 mmHg) or OH syndrome (n=18, AHI 58.7±38.0 PaCO2>46 mmHg), the HRV was analyzed, based on an 8 h ECG recording during sleep. In the OH patients, compared with the OSA patients, there was a globally decreased HRV, with a corresponding decrease in high frequency power in the spectral analysis of HRV and increased low frequency/high frequency ratio (p<0.05), indicating a reduced parasympathetic and increased sympathetic heart rate modulation. We conclude that hypoxemia and hypercapnia of the sleep disordered breathing have an impact on the autonomic heart rate regulation. HRV indices have a potential to become prognostic factors for the development of cardiovascular complications in patients with sleep disordered breathing.

Soluble ligand CD40 and uric acid as markers of atheromatosis in patients with obstructive sleep apnea

The aim of the study was to evaluate the risk of atheromatosis in patients with obstructive sleep apnea (OSA), as based on the concentration of the pro-atherogenic soluble CD40L ligand (sCD40L) in relation to the level of uric acid. The serum levels of sCD40L and uric acid were measured in 79 OSA patients (mean apnea/hypopnea index - AHI 34.4 ± 20.9) and in 40 healthy controls. We found that sCD40L was higher in the OSA patients with hyperuricemia than that in the patients with uric acid in the normal range (sCD40L: 9.0 ng/ml vs. 8.0 ng/ml, respectively, p < 0.05). There was a positive association of sCD40L with AHI (p = 0.01) and a negative one with the mean minimal nocturnal SaO₂(p < 0.05). Uric acid correlated negatively with the mean and minimal SaO₂and positively with the oxygen desaturation index (p < 0.05). OSA patients with hyperuricemia also had a higher prevalence of hypertension and ischemic heart disease. We conclude that OSA patients with increased uric acid concentration have increased risk of atheromatosis, as indicated by a higher level of soluble pro-atherogenic ligand CD40, and a higher prevalence of cardiovascular adverse events.

Efficacy of noninvasive mechanical ventilation in obese patients with chronic respiratory failure

Chronic respiratory failure (CRF) develops in a minority of obese patients. Noninvasive mechanical ventilation (NIMV) is a new optional treatment for such patients. The aim of this study was to evaluate the effectiveness of NIMV in obese patients with CRF. The material of the study consisted of 34 obese patients (body mass index 47.3 ± 7.9 kg/m(2)) with CRF (PaO2 = 6.40 ± 0.93 kPa and PaCO2 = 8.67 ± 2.13 kPa) who were hypoxemic despite an optimal therapy. Thirteen patients had an overlap syndrome (OS) - chronic obstructive pulmonary disease (COPD) coexisting with obstructive sleep apnea syndrome (OSAS) and 21 patients had obesity-hypoventilation syndrome (OHS). Ventilation parameters were determined during polysomnography. The efficacy of NIMV was evaluated on the fifth day and after 1 year's home treatment. We observed a significant increase in the mean blood oxygen saturation during sleep in all patients; the increase was greater in patients with OHS (92.6 ± 1.4 %) than in patients with OS (90.4 ± 1.8 %). There was a significant improvement of diurnal PaO2 and PaCO2 on the fifth day of NIMV (mean PaO2 increase 2.1 kPa and PaCO2 decrease 0.9 kPa) and also after 1 year of home NIMV (mean PaO2 increase 1.9 kPa and PaCO2 decrease 2.4 kPa). Only one patient stopped treatment because of lack of tolerance during the observation period (1-3 years). In conclusion, NIMV is an effective and well tolerated treatment option in obese patients with CRF resulting in a rapid relief of respiratory disorders during sleep and a gradual, long-term improvement of gas exchange during the day, particularly in patients with OHS.

[Concentrations of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in serum of patients with chronic obstructive pulmonary disease]

Chronic obstructive pulmonary disease (COPD) is characterized by the progressive destruction of the extracellular matrix of the lung. Matrix metalloproteinases (MMPs) and their inhibitors, especially tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), play a central role in the lung remodeling in COPD. Their concentrations in the sputum and bronchoalveolar lavage are considered as a sign of the local inflammation in COPD patients. The aim of the study was to evaluate of the MMP-9 and TIMP-1 serum concentration in COPD patients with respect to the correlation with a systemic inflammatory process.

MATERIAL AND METHODS

Thirty six COPD patients (29 male and 7 female) were enrolled into the study. Age-matched, healthy 15 subjects (11 male and 4 female) were selected as a control group. Serum levels of MMP-9, TIMP-1 and CRP were measured. The pre- and post-bronchodilator forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio were determined. The Spearman correlation was performed.

RESULTS

The serum MMP-9 concentration was significantly higher in the COPD patients than that in the control group (COPD: 194.8 +/- 129.1 ng x ml(-1); control subjects: 11.7 +/- 2.1 ng x ml(-1); p < 0.001). The serum concentration of CRP was significantly higher in the COPD patients than that in the control group (COPD: 14.3 +/- 6.3 ng x ml(-1); control subjects: 6.2 +/- 2.8 ng x ml(-1); p < 0.001). There was statistically significant correlation between the MMP-9 concentration and the CRP level in the serum of patients with COPD (p < 0.01; r = 0.45). There were no significant differences in the serum TIMP-1 concentrations between the control group and COPD patients. There was statistically significant, negative correlation between the FEV1 % of predicted value and the MMP-9 concentration (p = 0.03; r = -0.43).

CONCLUSIONS

MMP-9 may play an important role in the systemic inflammatory process in COPD. The serum concentrations of MMP-9 correlate with the stage of COPD.

Galectin-3 and cyclin D1 expression in non-small cell lung cancer

INTRODUCTION

Lung cancer is a major cause of mortality and morbidity worldwide. Galectin-3 is multifunctional protein, which is involved in regulation of cell growth, cell adhesion, cell proliferation, angiogenesis and apoptosis. Cyclin D1 together with other cyclin plays an important role in cell cycle control. Cyclin D1 regulates the G1-to-S phase transition. The aim of this study was the evaluation of correlations between clinicopathological findings and cyclin D1 and galectin-3 expression in non-small cell lung cancer (NSCLC). We wanted also to analyze the prognostic value of cyclin D1 and galectin-3 expression. Moreover we tried to evaluate the correlations between galectin-3 and cyclin D1 expression in tumor tissue.

MATERIALS AND METHODS

We used the immunochemistry method to investigate the expression of galectin-3 and cyclin D1 in the paraffin-embedded tumor tissue of 47 patients (32 men and 15 women; mean age 59.34 ± 8.90). years. We used monoclonal antibodies to cyclin D1 (NCL-L-cyclin D1-GM clone P2D11F11 NOVO CASTRA) and to galectin-3 (mouse monoclonal antibody NCL-GAL3 NOVO CASTRA).

RESULTS

Galectin-3 expression was positive in 18 cases (38.29%) and cyclin D1 in 39 (82.97%). We showed only weak trend, that galectin-3 expression was lower in patients without lymph node involvement (p = 0.07) and cyclin D1 expression was higher in this group (p = 0.080). We didn't reveal differences in cyclin D1 and galectin-3 expression in SCC and adenocarcinoma patients. We didn't demonstrated also differences in galectin-3 and cyclin D1 expression depending on disease stage. Moreover we analyzed the prognostic value of cyclin D1 expression and galectin-3 in all examinated patients and separately in SCC and in adenocarcinoma and in all stages, but we didn't find any statistical differences. We demonstrated that in galectin-3 positive tumors cyclin D1 expression was higher (96.55% vs 61.11%, Chi2 Yatesa 7.53, p = 0.0061) and we revealed negative correlation between cyclin D1 and galectin-3 expression (R Spearman -0.458, p = 0.0011). In squamous cell lung cancer we didn't observed correlations between these both examinated markers (R = -0.158, p = 0.460), and in adenocarcinoma the negative correlation was very strong (R = -0.829 p = 0.000132).

CONCLUSIONS

We didn't reveal any important correlations between clinicopathological findings and galectin-3 and cyclin D1 expression and in non small cell lung cancer. We didn't observed also prognostic value of cyclin D1 or galectin-3 expression. But we showed higher cyclin D1 expression in galectin-3 negative tumor tissues. We revealed also differences in correlations between galectin-3 and cyclin D1 expression in two main histopathological types of NSCLC.

[The cyclin A, B1, D1 and E expression in advanced non-small cell lung cancer--stages IIIB-IV (preliminary report)]

Lung cancer is the leading cause of cancer death in the majority of developed countries. Uncontrolled cell proliferation is the hallmark of malignant tumours. Cyclins play an important role in cell cycle regulation. The aim of this study was to evaluate the expression of cyclins A, B1, D1 and E in advanced non-small cell lung cancer (stages IIIB-IV) with its prognostic significance.

MATERIAL AND METHOD

An immunohistochemical assessment of cyclins A, B1, D1 and E expression was performed in the paraffin-embedded tumor tissues of 19 patients (9 men and 10 women). The mean was age 59 +/- 6.64 years. 9 patients were in IIIB and 10 in IV. The 2-years survival rate was evaluated.

RESULTS

We showed positive cyclin A expression in 13 tumor tissue specimens (68%), cyclin B1 in 3 (16%), cyclin D1 in 9 (47%) and cyclin E in 7 (37%). We analyzed the prognostic value of examinated cyclins in all NSCLC patients and separately in patients with squamous cell lung cancer and adenocarcinoma and in patients in stage IIIB and IV, but we have no found any correlations. We did not find also any differences in examinated cyclins expression depending on stages nor different histopathological types.

CONCLUSION

We did not observe prognostic value of cyclins A, B1, D1 or E expression in advanced non-small cell lung cancer.

Suppresion of Chronic Nocturnal Cough during Continuous Positiveairway Pressure (CPAP) Treatment in a Patient with Asthma Andobstructive Sleep Apnoea Syndrome

Sleep disruption may develop in patients suffering from chronic cough and in patients with obstructive sleep apnoea syndrome (OSAS). An increasing number of reports are being published that suggest a relationship between chronic nocturnal cough and the occurrence of breathing disorders during sleep characteristic of OSAS. We report a case of a 59-year-old obese male (BMI 38.6 kg/m2) suffering from asthma and chronic nocturnal cough irresponsive to optimal asthma treatment. Based on an examination of the patient’s breathing function during sleep we established the diagnosis of moderate OSAS and initiated continuous positive airway pressure (CPAP) treatment, as a result of which the cough resolved. The successful outcome of using CPAP in preventing episodes of nocturnal cough was further confirmed after a year of CPAP use. This case report justifies the inclusion of OSAS in the differential diagnosis of nocturnal cough, including nocturnal cough in asthma patients. The use of CPAP, which prevents the development of apnoeas and hypopnoeas, may also lead to the resolution of chronic nocturnal cough.

[Suppression of chronic nocturnal cough during continuous positive airway pressure (CPAP) treatment in a patient with asthma and obstructive sleep apnea syndrome]

Sleep disruption is a common feature both in the patients with chronic cough and in the patients with obstructive sleep apnea syndrome (OSAS). There is increasing body of evidence that chronic nocturnal cough may be related to OSAS. We describe a 59 years old, obese man (BMI 38,6 kg/m(2)) with asthma and chronic nocturnal cough not responding to the optimal anti-asthmatic treatment. On the basis of nocturnal polysomnography moderate form of the OSAS has been diagnosed and the treatment with continuous positive airway pressure (CPAP) has been started. All the nocturnal symptoms, including cough, disappeared. The effect of CPAP in preventing nocturnal cough persisted at the follow-up visit after a year since diagnosis. This case indicates that nocturnal cough may be an important symptom of the OSAS and CPAP treatment - by abolishing sleep apneas and hypopneas - may also prevent chronic cough during sleep.

[Nutritional knowlegde and lifestyle of obese patients with diagnosed obturative sleep apnea]

The study was aimed, therefore, at evaluating the nutritional knowledge and selected elements of lifestyle of obese patients with diagnosed obstructive sleep apnea (OSA), treated at the Lower Silesia Center of Pulmonary Diseases in Wroclaw. Assessment of nutritional knowledge was conducted among 49 patients including 12 women and 37 men with diagnosed obstructive sleep apnea (OSA), treated at the Lower Silesia Center of Pulmonary Diseases in Wroclaw. The nutritional knowledge and selected elements of lifestyle were evaluated by means of own-construct, standardized questionnaire elaborated at the Chair of Human Nutrition, Wroclaw University of Life and Environmental Sciences. It included questions from different fields referring to, among others: knowledge on rational nutrition, type of physical activity, frequency of cigarette smoking, etc. Despite the demonstrated some knowledge of good nutrition, its use by patients with OSA in everyday life raises many objections. This could possibly result from the message is not binding on the correct nutrition to their own health. Found in the studied group of patients with OSA obesity and low physical activity, evidence of the need to integrate into the process of treatment of individual dietary counseling.

[Chronic obstructive pulmonary disease and cardiovascular diseases]

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Patients with COPD are at increased risk of cardiovascular diseases, osteoporosis and lung cancer. Although some of the associations between COPD and atherosclerosis may be the result of common risk factors such as smoking, epidemiological evidence suggest that impaired lung function is a risk factor for increased cardiovascular death, independent of tobacco use. This phenomenon may be related to common genetic predisposition for atherosclerosis and emphysema. Chronic obstructive pulmonary disease, like atherosclerosis, is a disease of systemic inflammation and may hasten the progression of atherosclerosis and contribute to the higher rate of death in COPD. This article reviews close relationship between COPD and cardiovascular diseases, mainly atherosclerosis. The authors also present some preliminary data suggesting a possible influence of statin therapy on the clinical course of COPD.

[A case of kappa L-chain primary nodular lung amyloidosis]

Amyloidosis is a generic term for a heterogeneous group of disorders associated with deposition of protein in an abnormal fibrillar form. We report a case of kappa L-chain primary lung amyloidosis. A 44-year-old woman without symptoms. Roentgenogram and computed tomography of the chest showed several small nodular shadows. The mammography revealed tumor of the breast and the metastatic breast cancer have been suspected. After the quadrantectomy the breast tumor has been diagnosed as adenoma. The diagnosis of pulmonary amyloidosis was established by an open lung biopsy. Immunohistochemistry revealed amyloid light (AL) of kappa-light chain origin. Serum protein electrophoresis was negative for monoclonal gammapathy. Over the next 6 years, the patient remained relatively asymptomatic. The case illustrates the problems with diagnosis of multiple solitary nodules and the long and relatively benign course of primary pulmonary amyloidosis.

Bronchial hyper-responsiveness, subepithelial fibrosis, and transforming growth factor-beta(1) expression in patients with long-standing and recently diagnosed asthma

INTRODUCTION

Chronic inflammation in asthmatic airways leads to bronchial hyper-responsiveness (BHR) and the development of structural changes. Important features of remodeling include the formation of subepithelial fibrosis due to increased collagen deposition in the reticular basement membrane. Transforming growth factor (TGF)-beta might be a central mediator of tissue fibrosis and remodeling.

MATERIALS AND METHODS

Immunohistochemistry was used to measure collagen III deposition and TGF-beta(1) expression in biopsies from patients with long-standing asthma treated with inhaled corticosteroids, patients with recently diagnosed asthma, and control subjects. Computer-assisted image analysis was used to evaluate total basement membrane (TBM) thickness.

RESULTS

Asthmatics, particularly those with long-standing asthma, had thicker TBMs than healthy subjects. Collagen III deposition was comparable in the studied groups. BHR was not correlated with features of mucosal inflammation and was lower in steroid-treated patients with long-standing asthma than in subjects with newly diagnosed asthma untreated with steroids. Epithelial TGF-beta(1) expression negatively correlated with collagen III deposition and TBM thickness.

CONCLUSIONS

The study showed that TBM thickness, but not collagen III deposition, could be a differentiating marker of asthmatics of different disease duration and treatment. The lack of correlation between BHR and features of mucosal inflammation suggests the complexity of BHR development. Corticosteroids can reduce BHR in asthmatics, but it seems to be less effective in reducing subepithelial fibrosis. The role of epithelial TGF-beta(1) needs to be further investigated since the possibility that it plays a protective and anti-inflammatory role in asthmatic airways cannot be excluded.

[Changes in the percentage of activated lymphocytes in bronchoalveolar lavage fluid in patients with clinical improvement of sarcoidosis]

Sarcoidosis is characterized by an accumulation of the activated lymphocytes in affected organs. The aim of the study was the analysis of lymphocytes activation markers in a bronchoalveolar lavage fluid (BALF) in sarcoidosis and the influence of the disease outcome on the changes of cells subpopulations.

MATERIAL AND METHODS

We performed the study on 12 patients with the regression of sarcoidosis after the mean period of the observation 8.1 +/- 3.8 months.

RESULTS

We observed a tendency toward a BALF cellularity normalization: lowering of the percentage of CD4+ lymphocytes (mean: 67.1% vs. 57.8%, p = 0.047), lowering of the CD4+/CD8+ ratio (mean: 6.3 +/- 5.4 vs. 3.7 +/- 5.2, p < or = 0.05), lowering of the percentage of HLA-DR+ lymphocytes (mean: 65% < or = 16.4 vs. 43.9% +/- 18.0, p = 0.05), lowering of the percentage of CD25+ lymphocytes (mean: 5.7% vs. 3.1%, p < or = 0.05) and CD4+CD25+ (mean: 4.0% vs. 2.4%, p = 0.011).

CONCLUSION

The clinical improvement of sarcoidosis is accompanied by the lowering of the percentage of activated lymphocytes in BALF.

[Comparative evaluation of two health-related quality of life questionnaires in patients with sleep apnea]

Symptoms and complications of the obstructive sleep apnea (SAS) lead to a significant impairment of the health-related quality of life (HRQOL) of the affected individuals. Most HRQOL questionnaires have been published in English. Formal process of evaluation has to precede the introduction of a new language version of a HRQOL questionnaire. We conducted a comparative evaluation of the Polish versions of two HRQOL questionnaires: The Calgary Sleep Apnea Quality of Life Questionnaire (SAQLI) and The Functional Outcomes of Sleep Questionnaire (FOSQ). We examined the reliability, validity, stability and responsiveness of both questionnaires. Cronbach's alpha coefficient amounted to 0.94 for both questionnaires, which confirmed their reliability. Scores of both questionnaires highly correlated with measures of daily sleepiness, general health and SF-36 questionnaire scores. Both SAQLI and FOSQ gave stable results, but SAQLI was found to be more sensitive than FOSQ. The Polish version of FOSQ was proved to be a useful tool in cross-sectional assessment of HRQOL in patients with SAS. Stability and responsiveness of the Polish version of SAQLI and normal distribution of its scores make this questionnaire a preferable instrument in repeated assessments of HRQOL in the same group of patients.

[Serum and bronchoalveolar lavage fluid neopterin levels in patients with bronchial asthma]

Neopterin is an activation marker of macrophages. These cells become activated in bronchial asthma. The aim of the study was to measure serum and BALF neopterin levels in patients with bronchial asthma. The study included 15 patients with moderate, stable bronchial asthma. Serum neopterin levels were normal, while those in BALF were increased. The results of the study seem to indicate that in patients with moderate stable bronchial asthma alveolar macrophages are activated, as shown by increased levels of neopterin in BALF.

[Rhythm of melatonin excretion in obstructive sleep apnea syndrome]

Melatonin is a pineal hormone that regulates sleep and wake status. Melatonin concentrations in blood serum were measured using radioisotope method in 33 males (age 48 +/- 10) with obstructive sleep apnea syndrome. The following melatonin concentrations were measured: 54 +/- 72 pg/ml (9 p.m.) 424 +/- 838 pg/ml (2 a.m.) and 307 +/- 534 pg/ml (6 a.m.). In patients with high peak melatonin concentration (> 200 pg/ml) as compared with the patients with low peak melatonin concentration (< 200 pg/ml) there were higher index of respiratory disorders during sleep (53 +/- 18 vs 38 +/- 20, p < 0.05) and lower minimal SaO2 during sleep apnea (52 +/- 17% vs 70 +/- 10%, p < 0.05); they were also more tired in the morning and were more sleepy during the day (Epworth sleepiness scale 17 +/- 6 vs 11 +/- 6, p < 0.01). In 66% of patients peak melatonin concentration was observed at 2 a.m. In 24% of patients peak melatonin secretion was prolonged to early morning hours.

CONCLUSIONS

In most of patients there is peak melatonin excretion at 2 a.m. Patients with high apnea and hypopnea index and daytime sleepiness have high peak melatonin concentrations.

[Pulmonary alveolar microlithiasis in a patient with urolithiasis and cholelithiasis]

49 years old woman was admitted to Pulmonary Ward because of respiratory and cardiac failure. Six years earlier she was surgically treated because of urolithiasis and at this time disseminated lesions in both lungs were revealed. Biopsy made during transbronchial procedure showed microlithiasis. She had'nt any respiratory symptoms during 6 years. Now she had PaO2 = 36 mmHg and massive infiltrations in whole lungs. Palliative therapy with diuresis, cardiac drugs and oxygen therapy diminished symptoms of respiratory and cardiac failure.

[Lipoid pneumonia]

The authors describe in the article etiology, histopathological features, clinical picture and diagnostics of endogenous and exogenous lipoid pneumonia. The advantages of broncho-alveolar fluid examination and computed tomography in the diagnostics were emphasized.